Anavex Life Sciences Corp (AVXL)

[kld2]

Re-reading the Nov. 41-week data PR. Odd the price didn't skyrocket, with a paragraph like this:

"In comparison to historical control from a pooled placebo arm cohort study conducted by the Alzheimer Disease Cooperative Study Group in mild-to-moderate AD patients of comparable ages and MMSE baselines, over nine months the ANAVEX 2-73 data shows a potential treatment benefit of several points on both the MMSE scale and on the ADCS-ADL score."

Needs to be confirmed in larger study, as was said, but either the PR lied or it's pretty obvious that data next week will NOT be bad: "...shows a potential treatment benefit of SEVERAL points..."